RE:Just a questionYes you are definitely missing some things.
Whether one is worth more than another is up to the market. Why might the market be valuing them differently?
1) Medipharm has put out a lot more press releases around sales numbers. Right now unless you've called IR for Valens there is less visibility into what sales might look like. Market doesn't like that. The contracts are all like "a minimum of XXX" but that doesn't tell us much about reality.
2) Medipharm is actively buying large quantities of grass. While that might result in a lower margin, it results in a lot more flexibility potentially.
3) Valens is having issues with their greenhouse. So right now they don't have any capacity to grow and Medipharm is actively buying a bunch.
4) Again, valens hasn't provided enough transparency around revenues. There are published analyst numbers in their pitch deck, but even amongst investors on this board who have done a lot of diligence we have wildly different revenue numbers per gram.
For instance, lscfa is estimating $.50 / gram. However, TheBananaMan is estimating $1.25-2.50 / gram. That is WILDLY different in revenue numbers.
So I hold both and strongly believe both will be very successful. I also think Medipharm has done a better job on the PR side. But I also really love Valens having a lot of restraint around not pumping their brand much yet. I think with the hiring of Everett Knight that is actively changing.